HKSE:2410

TYK Medicines, Inc · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:26 UTC

Last close

n/aHKD

Market data

  • n/aP/E

    We do not hold this figure for this company, so there is nothing to place.

    Price / Earnings per Share (diluted)

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • computed
    • Computed from the filing for 2025
  • n/aROIC

    We do not hold this figure for this company, so there is nothing to place.

    NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aNet margin

    We do not hold this figure for this company, so there is nothing to place.

    Net Income / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aFCF margin

    We do not hold this figure for this company, so there is nothing to place.

    Free Cash Flow / Revenue x 100

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aDebt/equity

    We do not hold this figure for this company, so there is nothing to place.

    Total Debt / Shareholders' Equity

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • Computed from the filing for 2025
    • Computed from the filing for 2025
  • n/aDividend yield

    We do not hold this figure for this company, so there is nothing to place.

    Source
    computed
    Taken on
    2026-11-08
    Reported in
    HKD
    • computed

Five bars, one line

lens 7 of 9
n/a
0.87x
0.83x
0.35x
n/a
SalesProfitFree cash flowDebtPrice
Each bar against this company's own average; the line is that average.
Computed2025
Computed2025
Computed2025
Computed2025
Market datan/a

Each against its own average

3 of 5 read

Except where said otherwise: Computed from the filing for 2025

  • Salesn/a

    Its own average over 2 years, 22.2M.

  • Profit0.87x

    Its own average over 4 years, -345.0M.

  • Free cash flow0.83x

    Its own average over 4 years, -305.9M.

  • Debt0.35x

    Its own average over 4 years, 434.8M.

  • Pricen/a

    Its own average over 0 years. Market data

Debt is furthest from its own average, at 0.35 times.

Profit is 0.87 times its own 4-year average; Free cash flow is 0.83 times its own 4-year average; Debt is 0.35 times its own 4-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

  • Sales against its own 2-year averagen/a

    Not held.

    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • Profit against its own 4-year average0.87
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • Free cash flow against its own 4-year average0.83
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • Debt against its own 4-year average0.35
    Source
    computed
    Statement
    income
    Fiscal year
    2025
    Reported in
    CNY
  • Price against its own 0-year averagen/aMarket data

    Not held.

    Source
    market
    Reported in
    HKD

Filed figures cite the filing they come from; figures marked Market data are quotes as of the date shown. Not a recommendation and not advice.

Past figures are not a forecast. Anything we modelled is labelled as ours. You can lose money on any security.